Applied Genetic Technologies Long Term Debt

Applied Genetic Technologies (AGTC) currently reports a long-term debt of $11M as of September 2022. That compares with $19M in the prior-year period — down 43.8% year over year. Use the charts on this page to explore Applied Genetic Technologies's long-term debt history and peer comparisons.

Applied Genetic Technologies's long-term debt decreased from $19M to $11M — a 43.8% year-over-year decrease (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Applied Genetic Technologies reported $11M in long-term debt as of September 2022. That compares with $19M in the prior-year period — down 43.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $11M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Applied Genetic Technologies, and consider following AGTC for alerts when major investors trade the stock.

Applied Genetic Technologies is classified in the Healthcare sector. On long-term debt, it currently shows $11M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AGTC with unrelated industries.